Deep-pocketed investors have adopted a bearish approach towards Pfizer PFE, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in PFE usually suggests something big is about to happen.
We gleaned this information from our observations today when Benzinga's options scanner highlighted 12 extraordinary options activities for Pfizer. This level of activity is out of the ordinary.
The general mood among these heavyweight investors is divided, with 33% leaning bullish and 50% bearish. Among these notable options, 5 are puts, totaling $252,236, and 7 are calls, amounting to $697,672.
Expected Price Movements
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $20.0 to $35.0 for Pfizer over the last 3 months.
Analyzing Volume & Open Interest
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Pfizer's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Pfizer's substantial trades, within a strike price spectrum from $20.0 to $35.0 over the preceding 30 days.
Pfizer Option Volume And Open Interest Over Last 30 Days
Significant Options Trades Detected:
| Symbol | PUT/CALL | Trade Type | Sentiment | Exp. Date | Ask | Bid | Price | Strike Price | Total Trade Price | Open Interest | Volume |
|---|---|---|---|---|---|---|---|---|---|---|---|
| PFE | CALL | SWEEP | BULLISH | 03/21/25 | $1.15 | $1.12 | $1.15 | $26.00 | $229.8K | 16.0K | 2.2K |
| PFE | CALL | SWEEP | BEARISH | 03/21/25 | $0.49 | $0.48 | $0.48 | $27.50 | $192.3K | 20.5K | 4.9K |
| PFE | PUT | SWEEP | BEARISH | 05/16/25 | $0.57 | $0.55 | $0.56 | $24.00 | $118.9K | 6.9K | 0 |
| PFE | CALL | TRADE | BEARISH | 01/15/27 | $1.18 | $1.1 | $1.1 | $35.00 | $107.2K | 3.3K | 1.0K |
| PFE | CALL | SWEEP | BULLISH | 02/21/25 | $0.54 | $0.52 | $0.54 | $26.50 | $56.9K | 0 | 1.2K |
About Pfizer
Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
Following our analysis of the options activities associated with Pfizer, we pivot to a closer look at the company's own performance.
Current Position of Pfizer
- With a trading volume of 13,047,391, the price of PFE is up by 1.08%, reaching $26.59.
- Current RSI values indicate that the stock is is currently neutral between overbought and oversold.
- Next earnings report is scheduled for 14 days from now.
Professional Analyst Ratings for Pfizer
In the last month, 1 experts released ratings on this stock with an average target price of $29.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access. * Consistent in their evaluation, an analyst from UBS keeps a Neutral rating on Pfizer with a target price of $29.
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Pfizer options trades with real-time alerts from Benzinga Pro.
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
